OrthoPediatrics Corp. (KIDS)
| Market Cap | 394.28M -22.6% |
| Revenue (ttm) | 243.30M +14.5% |
| Net Income | -39.68M |
| EPS | -1.68 |
| Shares Out | 25.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,428 |
| Open | 15.79 |
| Previous Close | 15.06 |
| Day's Range | 14.54 - 15.79 |
| 52-Week Range | 14.42 - 23.70 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 24.67 (+60.72%) |
| Earnings Date | Apr 30, 2026 |
About KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruct... [Read more]
Financial Performance
In 2025, OrthoPediatrics's revenue was $236.35 million, an increase of 15.45% compared to the previous year's $204.73 million. Losses were -$39.65 million, 4.83% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for KIDS stock is "Strong Buy." The 12-month stock price target is $24.67, which is an increase of 60.72% from the latest price.
News
OrthoPediatrics Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% revenue growth, margin stability, and strong international and OPSB expansion. Guidance was raised for 2026, with new product launches and regulatory wins expected to drive further growth and profitability improvements.
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
WARSAW, Ind., April 16, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Transcript: 25th Annual Needham Virtual Healthcare Conference
Clinic expansion is ahead of schedule, with strong revenue and cash flow improvements. New enabling technologies and a robust product pipeline are driving growth, while international and digital initiatives are expanding. Financial outlook remains stable with improved margins and cash flow.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WARSAW, Ind., March 31, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...
OrthoPediatrics Transcript: The Citizens Life Sciences Conference 2026
A robust new product cycle is underway, with multiple launches in surgical, bracing, and enabling tech platforms planned through 2028. Financial performance is improving, driven by EBITDA growth, efficient set deployment, and specialty bracing expansion, while reduced competition from larger players creates new opportunities.
OrthoPediatrics Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 results included the first quarter of positive free cash flow and robust EBITDA growth. 2026 guidance targets 11%-13% revenue growth, $25M adjusted EBITDA, and break-even cash flow, driven by new product launches, international expansion, and a unique pediatric focus that limits competition.
OrthoPediatrics to Participate in Upcoming Conferences
WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Earnings Call Transcript: Q4 2025
Q4 2025 saw 17% revenue growth, record free cash flow, and strong gross margins, driven by innovation and international expansion. 2026 guidance projects 11%-13% revenue growth, $25M Adjusted EBITDA, and breakeven FCF, with a robust product pipeline and new market entries.
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
Record full year 2025 revenue of $236.3 million increased 15% compared to prior year Operating Cash flow improvement of $22 million in full year 2025 Generated $10 million of free cash flow in the fou...
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older OrthoPediatrics partner iotaMotion receives FDA cl...
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior year Initiates guidance for record Adjusted EBITDA in 2026
OrthoPediatrics Transcript: Piper Sandler 37th Annual Healthcare Conference
Guidance was reset to focus on predictable, high-margin growth, excluding volatile 7D and Latin America set sales. New product launches and international expansion are expected to drive growth from 2026, with a strong scoliosis and OPSB portfolio and significant EBITDA improvement anticipated.
OrthoPediatrics Transcript: Jefferies London Healthcare Conference 2025
A pediatric orthopedics-focused company is expanding its global reach and product portfolio through innovation, acquisitions, and education, targeting $233.5M-$234.5M revenue and $15M-$17M EBITDA in 2025. Specialty bracing and enabling technology drive growth, with free cash flow break-even expected in 2026.
OrthoPediatrics Transcript: Stifel 2025 Healthcare Conference
Trauma Deformity and OPSB divisions are driving strong growth, with new product launches and clinic expansion ahead of plan. Financial guidance has been rebased to a 12% baseline growth, focusing on profitability and cash flow, while a robust innovation pipeline and favorable market dynamics support long-term expansion.
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches
WARSAW, Ind., Nov. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Earnings Call Transcript: Q3 2025
Q3 2025 saw 12% revenue growth, strong core segment performance, and a 56% rise in adjusted EBITDA. Profitability and cash flow improved despite headwinds from 7D and LATSAM, with full-year guidance reaffirmed and positive free cash flow targeted for Q4.
OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results
WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family
WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025
WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics...
OrthoPediatrics Transcript: Guidance
Revenue guidance for 2025 was reduced due to delays in 7D capital sales and LATAM headwinds, with long-term growth now projected at 12%+ annually. Core segments remain strong, and free cash flow break-even is targeted for 2026, with improved working capital supporting profitability.
OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance
Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook Company to host conference call today, October 9th, 2025, to discuss the financial result...
OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System
WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedic...